- Home
- BCG vs MRSN Comparison
BCG vs MRSN Comparison
Compare BCG & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCG
- MRSN
- Stock Information
- Founded
- BCG 2016
- MRSN 2001
- Country
- BCG United States
- MRSN United States
- Employees
- BCG N/A
- MRSN N/A
- Industry
- BCG
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- BCG
- MRSN Health Care
- Exchange
- BCG Nasdaq
- MRSN Nasdaq
- Market Cap
- BCG 41.3M
- MRSN 40.7M
- IPO Year
- BCG N/A
- MRSN 2017
- Fundamental
- Price
- BCG $2.00
- MRSN $0.34
- Analyst Decision
- BCG
- MRSN Strong Buy
- Analyst Count
- BCG 0
- MRSN 5
- Target Price
- BCG N/A
- MRSN $5.75
- AVG Volume (30 Days)
- BCG 8.9K
- MRSN 3.0M
- Earning Date
- BCG 08-14-2025
- MRSN 08-12-2025
- Dividend Yield
- BCG N/A
- MRSN N/A
- EPS Growth
- BCG N/A
- MRSN N/A
- EPS
- BCG N/A
- MRSN N/A
- Revenue
- BCG $172,860,000.00
- MRSN $34,006,000.00
- Revenue This Year
- BCG N/A
- MRSN N/A
- Revenue Next Year
- BCG N/A
- MRSN $1.30
- P/E Ratio
- BCG N/A
- MRSN N/A
- Revenue Growth
- BCG 7.36
- MRSN N/A
- 52 Week Low
- BCG $1.71
- MRSN $0.26
- 52 Week High
- BCG $6.55
- MRSN $2.83
- Technical
- Relative Strength Index (RSI)
- BCG N/A
- MRSN 51.10
- Support Level
- BCG N/A
- MRSN $0.27
- Resistance Level
- BCG N/A
- MRSN $0.36
- Average True Range (ATR)
- BCG 0.00
- MRSN 0.03
- MACD
- BCG 0.00
- MRSN 0.01
- Stochastic Oscillator
- BCG 0.00
- MRSN 61.58
About BCG Binah Capital Group Inc. Common Stock
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.